Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Victor Levitan

Internal Medicine Highland Park, IL Medical Doctor

NPI 1912965401 CMS profile 41229

806 Central Ave Ste 103, Highland Park, IL 60035

Open in the dashboard

General payments

$4,320

195 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Victor Levitan of Highland Park, IL is reported in the CMS Open Payments database as having received $4,320 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,168 55
2024 General $1,914 90
2023 General $1,123 49
2022 General $116 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Victor Levitan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Victor Levitan were reported at $1,168. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Victor Levitan Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $116 $141 $42–$496 $149
2023 $1,123 $149 $45–$519 $160
2024 $1,914 $154 $47–$537 $164
2025 $1,168 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Pfizer Inc. $438 21 payments
  2. Novo Nordisk Inc $437 18 payments
  3. AstraZeneca Pharmaceuticals LP $347 17 payments
  4. AbbVie, Inc. $319 14 payments
  5. GlaxoSmithKline, LLC. $294 14 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $280 11 payments
  7. Sumitomo Pharma America, Inc. $197 11 payments
  8. Lilly USA, LLC $189 9 payments
  9. Amgen Inc. $161 7 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $151 7 payments
  11. Other $1,508 66 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,236 193 payments
  2. Education $85 2 payments
Products named General payments · program years 2022–2025
  1. Kerendia $280 11 payments
  2. COMIRNATY $244 10 payments
  3. TRELEGY ELLIPTA $232 11 payments
  4. PREVNAR 20 $229 9 payments
  5. ABRYSVO $229 9 payments
  6. GEMTESA $197 11 payments
  7. AIRSUPRA $197 9 payments
  8. AREXVY $183 9 payments
  9. RYBELSUS $179 4 payments
  10. NURTEC ODT $175 11 payments
  11. Other $3,836 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

1,778

Median for Internal Medicine: 777

Drug cost

$88,536

Median for Internal Medicine: $73,373

Branded share of claims

15.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 24 $24,904
Jardiance Empagliflozin Brand 14 $24,682
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $7,938
Pregabalin Generic 15 $2,404
Atorvastatin Calcium Generic 139 $1,727
Levothyroxine Sodium Generic 123 $1,559
Amlodipine Besylate Generic 110 $1,377
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 17 $1,248
Montelukast Sodium Generic 74 $1,192
Gabapentin Generic 71 $1,170

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$11,875

Medicare's payments for the services billed

Medicare patients

90

Average age 78

Services billed

155

35 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 54%
Arthritis 28%
Ischemic heart disease 20%
Diabetes 18%
Atrial fibrillation 18%
Osteoporosis 17%
Heart failure 14%
Chronic kidney disease 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $152
$152 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $124
$124 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $113
$113 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $97
$97 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $86
$86 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record